Pharma & Biotech Global Week in Review 23 June 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Highlights this week included:

EU: AG opinion out on C-229/09 Lovells v. Bayer CropScience AG– Can a supplementary protection certificate based on a provisional marketing authorisation be granted? (EPLAW) (SPC blog)

Viagra (Sildenafil) – Brazil: Snag in early end to Viagra patent in Brazil (IP Watch)

General

Medical patents – are they necessary evils? (Patent Baristas)

Biotechnology management papers 2010 (Biotech Blog) (Biotech Blog)

Nanofutures – the future of Nanotechnology IP? (Tangible IP)

Australia: Report on Australian Senate Enquiry into gene patenting delayed again (Patentology)

EU: European Pharma leads the way on access to medicines (IAM)

EU: AG opinion out on C-229/09 Lovells v. Bayer CropScience AG– Can a supplementary protection certificate based on a provisional marketing authorisation be granted? (EPLAW) (SPC blog)

Germany: Federal Supreme Court ruling on obviousness in the field of drugs – Fettsäurezusammensetzung (fatty acid composition) (EPLAW)

Korea: The continuing saga of faked Korean stem cell research (Patentology)

US: Senator Nelson takes another crack at the Drug Price Competition Act (FDA Law Blog)

US: Myriad Appeals AMP v. USPTO decision: Association for Molecular Pathology v. U.S. Patent and Trademark Office (Patent Docs) (Patentology)

US: BIO celebrates anniversary of Chakrabarty decision (Patent Docs)

Products

Allegra (Fexofenadine) – US: Sanofi-Aventis secures injunction against Dr. Reddy’s over generic Allegra (Patent Docs)

Combigan (Brimonidine) – US: Patent infringement complaint following a Para IV certification: Allergan, Inc. v. Apotex, Inc. et al. (Patent Docs)

Cydectin (Moxidectin – US: CAFC decision regarding when testing phase ends and approval phase begins for NADA in PTE case Wyeth Holdings Corp. v. Sebelius (Patent Docs)

Hectorol (Doxercalciferol) – US: Patent infringement complaint following a Para IV certification: Genzyme Corp. v. Anchen Pharmaceuticals Inc. et al. (Patent Docs)

Kremezin / Krenosin – EU: KREMEZIN too close to KRENOSIN for pharma goods, rules General Court: Kureha Corp v OHIM (Class 46)

Prilosec (Omeprazole) – US: District Court S D New York: Apotex found not to have wilfully infringed AstraZeneca Prilosec patents (Patent Docs)

Solodyn (Minocycline hydrochloride) – US: Patent infringement complaint following a Para IV certification: Medicis Pharmaceutical Corp. v. Mylan Inc. et al. (Patent Docs) (Patent Docs)

Sutent (Sunitinib) – US: Patent infringement complaint following a Para IV certification: Pfizer Inc. et al. v. Mylan Inc. et al. (Patent Docs)

Trilipix (Fenofibrate) – US: Patent infringement complaint following a Para IV certification: Abbott Laboratories et al. v. Anchen Pharmaceuticals, Inc. (Patent Docs)

Viagra (Sildenafil) – Brazil: Snag in early end to Viagra patent in Brazil (IP Watch)

Yaz (Drospirenone and ethinyl estradiol) – US: Patent infringement and false advertising complaint based on generic Yaz product, Gianvi: Bayer Schering Pharma AG et al. v. Teva Pharmaceuticals USA, Inc. et al. (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: